Abstract: A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines (PC-3, LNCaP, and DU145) were evaluated by a CCK-8 assay. Compounds 9 and 15 exhibited strong cytotoxic activities against LNCaP cells (IC 50 < 5 μM), and compound 8 (IC 50 = 8.25 μM) possessed the most potent activity against DU145 cells. However, these compounds also exhibited cytotoxicity towards human epithelial prostate normal cells RWPE-1. The structure-activity relationship (SAR) of these arylpiperazine derivatives was also discussed based on the obtained experimental data.
Introduction
Prostate cancer is the most common non-skin cancer in men and is the second-leading cause of cancer-related deaths in the US [1] . The incidence of prostate cancer varies worldwide. Generally, the Recent studies have shown that naftopidil could possibly exert an anticancer effect and inhibit prostate cancer cell growth by arresting the G1 cell cycle phase [33, 34] . In addition, naftopidil can also decrease cell viability for bladder, prostate, and renal cancer cell lines [35] , as well as induce apoptosis in malignant mesothelioma cell lines [36] . These findings indicate that naftopidil might be useful as an anti-cancer drug. Many studies have shown that arylpiperazine derivatives may act as potential α1a-and/or α1a-+ α1d-selective ligands for the treatment of BPH. However, there have been few studies on cytotoxic activities of these compounds against human prostate cancer cells [37] [38] [39] [40] [41] [42] . As part of our group's continuing efforts to study the core framework of naftopidil [43] [44] [45] [46] , herein we report the synthesis of a series of novel arylpiperazinyl derivatives based on naftopidil (Scheme 1) to identify new anti-prostate cancer drug candidates with potential for further development. All synthesized compounds were evaluated for their cytotoxic activities against the androgen-insensitive human prostate cancer cell line PC-3, the androgen-sensitive human prostate cancer cell line LNCaP, the androgen-insensitive human prostate cancer cell line DU145, and the human prostate epithelial cell line RWPE-1. The SAR was further discussed on the basis of the obtained experimental data. Some compounds exhibited strong anti-cancer activities against the tested cancer cells and superior potency than naftopidil. 
Results and Discussion

Chemistry
As depicted in Scheme 1, a series of novel arylpiperazine derivatives were synthesized in four steps starting from the commercially available 2-(4-(bromomethyl)phenyl)acetic acid (1). First, compound 1 was reduced to alcohol 2 in the presence of a borane-methyl sulfide complex (2 M in tetrahydrofuran) at 0 °C for 1 h and then at room temperature for 10 h. The intermediate 2 was directly used without further purification. The nucleophilic substitution reaction of compound 2 with sesamol in the presence of potassium carbonate (K 2 CO 3 ) gave compound 3 (67% yield from compound 1) after 16 h at reflux. Compound 3 was treated with 4-toluenesulfonyl chloride in the presence of triethylamine and a catalytic amount of 4-dimethylaminopyridine at 0 °C for 16 h to generate compound 4 (95% yield). Finally, the reactions of compound 4 with various arylpiperazines or phenyl-piperidines in the presence of K 2 CO 3 at reflux for 16 h gave arylpiperazine or phenylpiperidine derivatives 5 to 29 (55% to 82% yield; Scheme 1). The structures of all the compounds (as their HCl salts) were confirmed using 1 H-NMR, 13 C-NMR, and elemental analyses (C, H, and N).
Cytotoxic Activity
The synthesized target compounds 5 to 29 were evaluated for their in vitro cytotoxic activities against the three human prostate cancer cell lines (PC-3, LNCaP, and DU145), and compared with their effects on human prostate epithelial cell line RWPE-1 by CCK-8 assay [47] [48] [49] . The results are summarized in Table 1 . 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  naftopidil   >50  >50  >50  >50  >50  >50  >50  >50  >50  >50  >50  >50  >50  26.89 ± 1.00  >50  >50  >50  >50  >50  >50  >50  >50 As shown in Table 1 , some compounds exhibited moderate to strong cytotoxic activities against the tested cancer cell lines, and even exhibited much better activity than naftopidil. For example, compounds 9 and 15 exhibited strong cytotoxic activities against LNCaP cells (IC 50 < 5 μM) and these compounds showed excellent selective activity for LNCaP cells over the other tested cancer cells. However, compounds 9 and 15 exhibited cytotoxic effects on normal RWPE-1 human epithelial prostate cells. Moreover, compound 8 (IC 50 = 8.25 μM) showed the most potent activity against DU145 cells and a marked selectivity for DU145 cells over the other tested cancer cells.
The SAR analysis revealed the following: (1) phenylpiperazine derivative 5 exhibited similar cytotoxic activities against LNCaP cells compared with benzylpiperazine derivative 6, however, these activities decreased significantly in DU145 cells; (2) compound 8 exhibited a more effective cytotoxic activity than compounds 5 and 7 against DU145 cells. These results suggest that the introduction of a pyrimidinyl moiety at the 4-position of piperazine ring was beneficial for anti-cancer activity. Moreover, compound 8 showed excellent selective activity for DU145 cells over the other tested cancer cells; (3) compound 11 lost potency (IC 50 > 50 μM) against LNCaP cells compared with compounds 9 and 10 (IC 50 = 3.47 and 31.94 μM, respectively). The activity profiles indicated that a methyl at the m-position on the phenyl group was inauspicious for anti-cancer activity. A similar potency profile was observed in compounds 12, 13, and 14; (4) Moreover, compounds containing an omethyl-substituted phenyl group showed better activity for LNCaP cells than did the p-methylsubstituted group for LNCaP cells, as exemplified by compound 9 which showed significantly improved activity, while compound 10 exhibited moderate cytotoxic activity. A similar potency profile was also observed in compound 15 (IC 50 = 1. Table 1 , compounds 28 and 29 exhibited moderate cytotoxic activities against LNCaP and DU145 cells. However, these compounds also exhibited cytotoxic effect on human prostate epithelial cell line.
Experimental Section
General Information
Reagents and solvents were commercially available. Solvents were dried and purified prior to use using standard procedures. Melting points were determined on a SGW X-4 micro melting point apparatus (Shanghai Precision & Scientific Instrument Co., Ltd, Shanghai, China) and are uncorrected. NMR spectra were determined on a Bruker AV-400 NB spectrometer (Faellanden, Switzerland) in DMSO-d 6 using TMS as internal standard, and coupling constants (J) are in Hz. EI mass spectra were recorded on a DSQ mass spectrometer. Elemental analyses (C, H, N) were performed on an Elementar Vario EL elemental analyzer and the analytical results were within ±0.4% of the theoretical values for the formula given unless otherwise listed. Flash column chromatography was performed with silica gel (300-400 mesh, Qing Dao Ocean Chemical Factory, Qingdao, China) eluted with petroleum ether-ethyl acetate.
To a cooled (0 °C) solution of carboxylic acid 1 (5 g, 0.021 mol) in dry tetrahydrofuran (THF, 100 mL) borane-dimethyl sulfide complex (21.9 mL, 0.042 mol, 2 M in THF) was added dropwise. The reaction mixture was stirred at 0 °C for 1 h and at room temperature for 10 h. Water (20 mL) was added slowly and extracted with ethyl acetate (3 × 100 mL). The combined organic phase was successively washed with water, brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue was directly used without further purification in the following step.
To a solution of compound 2 (4 g, 18.7 mmol) in acetone (100 mL) sesamol (2.58 g, 18.7 mmol） and potassium carbonate (10.32 g, 74.8 mmol) were added, and the reaction mixture was stirred at reflux for 16 h. After cooling to ambient temperature, the reaction mixture was filtered through a Buchner funnel. After filtration the filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography using ethyl acetate/petroleum ether (1/10, v/v) as eluent to afford 4.06 g of compound 3 (67% from compound 1) as a white solid. m.p. 102-103 °C; 
2-(4-((Benzo
To a solution of compound 3 (4 g, 14.7 mmol), triethylamine (5.94 g, 58.8 mmol) and 4-dimethyl-aminopyridine (0.18 g, 1.47 mmol) in dry dichloromethane (CH 2 Cl 2 , 100 mL) at 0 °C was added dropwise a solution of 4-toluenesulfonyl chloride (4.19 g, 22.1 mmol) in CH 2 Cl 2 (10 mL). The reaction mixture was stirred at 0 °C for 16 h. Water (20 mL) was added slowly and the reaction mixture was extracted with CH 2 Cl 2 (3 × 100 mL). The combined organic phase was successively washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. 
General Procedure for the Preparation of Compounds 5-29
To a solution of 4 (100 mg, 0.23 mmol) in acetonitrile (CH 3 CN, 10 mL) was added the corresponding arylpiperazine or phenylpiperidine (1.2 equiv) and potassium carbonate (6.0 equiv). The reaction mixture was stirred at reflux for 16 h. After cooling to ambient temperature, the reaction mixture was filtered through a Buchner funnel. After filtration the filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography using ethyl acetate/petroleum ether (1/5, v/v) as eluent to afford the corresponding products, and all compounds were recrystallized from trichloromethane and n-hexane. (12) . Yield: 75%, m.p. 173-174 °C (HCl salt); (14) . Yield: 72%, m.p. 171-172 °C (HCl salt); (15) . Yield: 65%, m.p. 187-188 °C (HCl salt); (16 (19) . Yield: 78%, m.p. 176-177 °C (HCl salt); (20) . Yield: 70%, m.p. 164-165 °C (HCl salt); (25 (27) . Yield: 60%, m.p. 183-184 °C (HCl salt); [d] [1, 3] 
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